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Background
December 2019, Wuhan, China: a novel virus 
caused the first cases of pneumonia. Since then, se-
vere acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) has rapidly spread worldwide, leading the 
World Health Organization to declare the global pan-
demic on 11th March 2020. As of 26 July 2020, the 
WHO reported 15.785.641 cases with over 640.016 
deaths.
Compared to adults, children initially seemed to 
be less affected and to develop a milder disease. Since 
the end of April 2020, however, several reports have 
described the occurrence in children of a severe multi-
system inflammatory syndrome resembling Kawasaki 
disease, temporally related to COVID-19 infection. It 
is not already clear if this is a distinct clinical entity. 
The present review aims to summarize the recent lit-
erature about this topic.
Methods
A literature search was conducted using Pubmed. 
The terms Children AND COVID-19 OR coronavirus 
AND inflammatory syndrome OR Kawasaki disease 
were used, and filters including only articles about the 
pediatric population. Most of the publications were 
single case reports, small case series or literature re-
views.
Summary. Current data suggest that during the global pandemic of COVID 19 children are less affected 
than adults and most of them are asymptomatic or with mild symptoms. However, recently, cases of pediatric 
patients who have developed severe inflammatory syndrome temporally related to SARS-CoV-2 have been 
reported both in USA and Europe. These reports, although sharing features with other pediatric syndromes 
such as Kawasaki disease (KD), Kawasaki disease shock syndrome (KDSS), macrophage activated syndrome 
(MAS) and shock toxic syndrome (TSS), seem to outline a novel entity syndrome, characterized by cytokine 
storm with elevated inflammatory markers and typical clinical finding. Clinical characteristics are greater me-
dian age than KD, higher frequency of cardiac involvement and gastrointestinal symptoms, lower frequency 
of coronary anomalies. We report a summary of the current evidence about clinical features, pathogenesis, 
therapy strategies and outcome of this novel syndrome. 
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Covid-19 in Children
The real prevalence of SARS-COV-2 infection in 
children is not unknown. 
One of the first epidemiologic studies comes from 
China, the source of the pandemic: of the 2143 pediat-
ric patients reported by Dong et al., the majority were 
asymptomatic or with mild to moderate symptoms (1). 
The percentage of patients with severe forms was sig-
nificantly lower than adults (5.9% vs 18.5%, p<0,05) 
with the highest peak of severe forms in the category 
0-5 years and a very low mortality rate (0.1%) (1). It 
has been supposed that the lower severity of the pedi-
atric forms was associated with environmental factors 
(lower exposure to pathogenic agents) and immu-
nogenic factors (developing immune system, lower 
 expression of Angiotensin Converting Enzyme 2 re-
ceptors, ACE2, on the target tissues) (2), but reasons 
for this difference remain to be determined. 
A more recent systematic review analyzed 18 
Chinese studies with 1065 participants (444 patients 
were younger than 10 years, and 553 were aged 10 
to 19 years) with confirmed SARS-CoV-2 infection 
(3). The authors concluded that the most common 
pediatric presentation of COVID-19 was an array of 
signs and symptoms, from completely asymptomatic 
to symptoms of acute upper respiratory tract infection 
such as fever, fatigue, cough, sore throat, rhinorrhea 
and congestion, and shortness of breath. Compared to 
adults, children rarely progressed to severe upper res-
piratory symptoms requiring intensive care unit admis-
sion. Also, cutaneous features have been described in 
children in relation to SARS-COV-2 infection, with 
peculiar attention on chilblains, one of the hallmarks 
of some rheumatologic disorders (4).
However,  data underline that COVID-19 may 
have a non-negligible rate of severe presentation espe-
cially for children with comorbidities, as seen by two 
Italian research networks published by Parri et al.(5)
Although most children have an uneventful 
course, reports from Europe and America presented 
concern about an inflammatory cascade in pediatric 
patients with COVID-19, whose clinical presentation 
overlaps with Kawasaki disease (KD), macrophage ac-
tivated syndrome (MAS), Kawasaki disease shock syn-
drome (KDSS) or toxic shock syndrome (TSS) (6-11). 
Kawasaki Disease
KD is a rare acute vasculitis of the medium and 
small vessels. According to the Italian guidelines pub-
lished in 2018, (12) diagnostic criteria of typical or 
complete KD are the presence of > 5 days of fever and 
> 4 of the followings: bilateral non-exudative conjunc-
tivitis, erythema of the lips and oral mucosa, changes in 
extremities, skin rash and cervical lymphadenopathy.
Incomplete KD occurs in patients presenting 
a typical fever without a sufficient number of main 
clinical criteria, while atypical KD presents the typi-
cal fever associated to signs and symptoms that dif-
fer from the classical ones (meningeal inflammation, 
gastrointestinal symptoms, acute abdomen, arthritis, 
pneumonia,…).
A small percentage of patients can develop a more 
severe form of KD, known as KDSS, and defined on 
the basis of systolic hypotension for age, sustained de-
crease in systolic blood pressure from baseline of >20% 
or clinical signs of poor perfusion. 
KD has potential serious cardiac complications, 
as the coronary artery aneurisms (CAA), and remains 
the primary cause of acquired heart disease in devel-
oped countries.
The etiology is still unclear, although it is believed 
to be a strong inflammatory response to an infectious 
trigger in genetically predisposed individuals. Evi-
dence of a viral role in triggering KD is suggested by 
seasonal epidemic trend (13).
A number of viruses have been implicated in KD 
etiology, and coronavirus family has been proposed as 
possible related cause.  The identification of a higher 
percentage of new coronavirus (HCoV-NH) in the 
respiratory secretions of patients with Kawasaki than 
controls (72% vs 4,5%) was described by Esper et.al 
(14), but subsequent studies gave conflicting results 
(15, 16). 
The possible role of SARS-COV-2 in pathogen-
esis of ‘classic’ KD is still missing, but current evidence 
does not seem to support this hypothesis. 
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Clinical Features: An Overlapping Syndrome
Jones et al. described the first case of concurrent 
COVID-19 and Kawasaki disease: the authors just de-
tailed the case of a 6-month-old infant, who presented 
all the criteria for complete KD and also positive RT-
PCR testing for COVID-19. The patient was success-
fully treated with IVIG and acetylsalicylic acid (7).
Since the end of April 2020, several case reports 
from Europe and US described children presenting a 
severe inflammatory syndrome temporally related to 
SARS-CoV 2 infection, and overlapping with KD, 
MAS17, KSS(18) and TSS(19) (Table 1).
This occurrence led to alerts and guidelines from 
various scientific societies, which used different ac-
ronyms: the Royal College of Pediatrics and Child 
Health ((RCPCH)(20) defined PIMS-TS acronym 
(Pediatric Inflammatory Syndrome Temporally asso-
ciated with SARS-CoV-2); the Centers for Disease 
Control and Prevention (CDC)(21) described this 
syndrome under the label MIS-C (Multisystem In-
flammatory Syndrome in Children). Also, the Italian 
Istituto Superiore di Sanità published recommenda-
tions on the topic at the end of May 2020 (22).
Table 2 summarizes case definitions and diagnos-
tic criteria proposed by the scientific societies. 
The first reports appeared in UK (8, 23) and Italy 
(6, 10) followed by France (9, 11, 24, 25), New York 
and other regions of the US (7, 26).
The first case series from UK showed a cluster 
of 8 patients with hyperinflammatory shock, which 
required inotropic support (8). The majority of these 
cases were of Afro-Caribbean origins; clinical pres-
entations were similar to classic KD, with significant 
gastrointestinal involvement, while laboratory findings 
detailed high inflammatory indices and myocardial in-
jury. One of these patients died, due to cerebrovascular 
accident that followed extracorporeal membrane oxy-
genation (ECMO).
Moreover, Ramcharan et al. performed a retro-
spective study, and described 15 cases over 1-month-
study period (23). Clinical and biochemical features 
were similar: median age of 8.8 years, Afro-Caribbean 
or South Asian origins, predominant gastrointestinal 
symptoms (87%) cardiac involvement (100%) and 
shock/hypotension signs (67%). In these series many 
coronary abnormalities (53%) were detailed, such as 
prominent, dilated or aneurysmal coronaries, but in 
about half of the cases, they normalized before dis-
charge.
The Italian case series from Bergamo described 
10 patients admitted to the emergency department 
during COVID-19 pandemic and diagnosed as KD 
(6). The cases were compared with a historical co-
hort of KD patients: the first, named Kawasaki-like, 
were older (mean age 7.5), had respiratory and gas-
trointestinal involvement, meningeal signs, and signs 
of cardiovascular impairment.  From a biochemical 
perspective, they had leucopenia with marked lym-
phopenia, thrombocytopenia, and increased ferritin, 
as well as elevated markers of myocarditis. Comparing 
epidemiologic data, the authors reported a monthly 
incidence at least 30 times greater than the previous 
5 years. Kawasaki-like patients had a more severe disease 
course, with resistance to intravenous immunoglobulin 
(IVIG) and need of adjunctive steroids, biochemical 
evidence of MAS and clinical signs of KDSS. 
Moreover, Licciardi et al. detailed two case re-
ports, 12-years-old and 7-years-old boys, presented to 
the Pediatric Department of Turin (Italy) in mid-April 
2020, both featuring an hyperinflammatory  syndrome 
and evidence of previous SARS-CoV-2 infection 
(high IgG titers) (10). These cases share clinical and 
laboratory findings. The authors tried to divide the 
syndrome in 3 different clinical phases: in phase 1 the 
patient had high fever, gastrointestinal symptoms and 
elevated inflammatory markers, mimicking gastroin-
testinal bacterial infection; phase 2 was characterized 
by mucocutaneous involvement resembling KD, but 
also progressive thrombocytopenia and capillary leak 
syndrome (not frequent in KD) with hypoalbumine-
mia, diffuse edema, hypotension requiring fluid resus-
citation therapy; lately, myocarditis appeared (phase 3), 
with slow improvement of cardiac function. Licciardi 
et al. underlined an overlapping between this disease 
and KD complicated with MAS, with some differ-
ences: absence of coronary involvement, development 
of myocardial dysfunction and rapidly progressive 
capillary leak syndrome. Interestingly, authors noted 
similarities between this syndrome and Feline Infec-
tious Peritonitis, a fatal immune-mediated disease, 
characterized by fluid accumulation in body cavities, 
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Table 1: Comparison between syndromes than can overlap with new reported pediatric Covid-19 cases (Paediatric Inflammatory 
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volume resuscitation 
+/- infusions of vaso-
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Outcomes Extremely low death rate









sisted in chronic 
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Possible evolution with 
progressive multi-organ 
failure and eventually a 
fatal outcome if unrec-
ognized.
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CRP: C reactive protein; PCT: procalcitonin, WBC: white blood cells, ESR: erythrocyte sedimentation rate; BNP: brain natri-
uretic peptide, KD: Kawasaki disease. IVIG: intravenous immune globulin





























































































































































































teroids if the 
state persists
No alternative plausible diagnoses; AND positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or 
antigen test; or exposure to a suspected or confirmed COVID-19 case within the 4 weeks prior to the onset of symptoms.
CRP: C reactive protein; PCT: procalcitonin, WBC: white blood cells, ESR: erythrocyte sedimentation rate; BNP: brain natri-
uretic peptide, LDH: lactic acid dehydrogenase, IL6: interleukin 6
Table 2: Comparison between guidelines and diagnostic criteria proposed by RCPCH, CDC and ISS.
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as a consequence of immune complex deposition and 
macrophage activation. Interestingly, gastrointestinal 
symptoms in KD have been previously related to a 
more severe course of the disease, with higher rates of 
IVIG-resistance (27).
Similar clinical and biochemical characteristics, 
treatment and outcome are detailed in French case 
series, which contain information about 21 cases 
(11) plus 16 cases (25), occurred in Paris. The authors 
underlined age greater than 5 years and elevated fer-
ritin (> 1400 mcg/l) as features of severe prognostic 
value (25).
In addition, Belhadjer et al. reported 35 cases of 
children with acute heart failure and severe inflamma-
tory state from France and Switzerland (9). Despite a 
similar presentation, comorbidities were found in 28% 
of the cases, especially asthma and overweight, this 
latter already reported as risk factor in other reports 
(11.25). During the same period, 100 cases with simi-
lar presentation were identified from the New York 
State Department of Health. 
We also reported here the case series from Chio-
tos el al. (25). Although the clinical signs similar to the 
previous case series, this time patients also presented 
with a high percentage of neurological involvement 
(4:6 66%) (Table 3).
Myocardial implications seem to be a hallmark of 
this hyper-inflammatory state, whereas coronary aneu-
rysms are the hallmark of KD.
Therefore, despite some similarities, there are 
epidemiological clinical and laboratory evidences sup-
porting the concept of a new syndrome, separated 
from KD and also from MAS and TSS.
Pathogenesis
Almost all of the patients described showed posi-
tivity to IgG antibodies for SARS-CoV-2, while only 
a little percentage was found positive to nasopharyn-
geal swab: these findings suggest a late onset of the 
disease compared with the primary infection, due to 
the host immune response.
Increasing evidence is suggesting that tissue dam-
age in COVID-19 is mostly mediated by the host 
innate immunity, which activates a cytokine storm 
resembling the macrophage activation of the viral- 
induced hemophagocytic lymphohistiocytosis (28, 29). 
New evidences of the COVID-19 immune response 
appear to emerge from a recent histopathology study 
(30) The authors reported the unbalance escalation 
from Th2 immune response to type 3 hypersensitivity, 
with the subsequent deposition of antigen-antibody 
complexes particularly inside the walls of blood ves-
sels, the activation of complement factors (C3a and 
C5a) and the release of cytokines able to generate an 
acute necrotizing vasculitis. 
A cytokine storm syndrome with increased levels 
of inflammatory markers such as IL-6 was described 
in adults with COVID-19, and it has been associated 
with fatality (31). This storm is reflected clinically by 
heart failure, pneumonia, gastrointestinal, neurological 
and renal features, associated with elevated CRP lev-
els, ferritin and cytokines (IL-1, IL-6, TNFalfa).
Genetic studies investigating the susceptibility 
of patients developing the severe disease triggered by 
SARS-CoV-2, should be performed.
Epidemiology
Precise epidemiological data regarding the in-
flammatory syndrome temporally related to SARS-
CoV-2 are not yet available, but several countries 
including Italy, France, Spain and UK have started 
national registries.
The first results from French national surveillance 
reported 108 PIMS cases from 1 March to 17 May 
(24). The epidemic curve revealed a sharp increase in 
incidence after 13 April, culminating 4-5 weeks af-
ter the peak of the COVID-19 epidemic in France, 
and decreasing thereafter. These results, together with 
the correlation between geographical distribution of 
COVID-19 cases and Kawasaki-like patients, support 
a causal relationship between SARS-CoV-2 infection 
and PIMS. The timing of 4-5 weeks supports the hy-
pothesis of PIMS being a post-infectious manifesta-
tion. One death was recorded in this case series. 
The absence of reported cases of Kawasaki-like 
multisystem inflammatory syndrome associated with 
SARS-CoV-2 infection in Asia countries where the 
COVID-19 pandemic started, and where the incidence 
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Table 3: Comparison between clinical and biological features of reports about inflammatory syndrome SARS-CoV2 probably related
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Only a few children required additional therapies, 
such as anakinra (recombinant IL-1 antagonist).
Another potential treatment is tocilizumab, an 
IL-6 inhibitor used in setting of refractory KD, but 
caution has to be used because of one report that dem-
onstrated rapid development of coronary artery aneu-
rism (CAA) following the therapy (33). 
Belhadjer described 35 cases from France and 
Switzerland: all patients received IVIG, with adjunc-
tive steroids in one third; inotropic support was needed 
by the majority of critical children, 28% of which were 
treated with ECMO with good outcome.
Antiviral therapy with remdesivir may be con-
sidered for SARS-CoV-2 RT-PCR positive patients, 
as studies have shown that its benefit is greatest when 
administered in early disease (34, 35).
Overall mortality has been low, with a single 
death in the UK cohort (due to cerebrovascular acci-
dent while on ECMO) (8), one death reported from 
French surveillance (24) and four reported deaths in 
US (36). 
Conclusions
The knowledge about the hyperinflammatory 
syndrome, and its relationship to KD, is evolving. 
Current evidence underlines some notable differences 
between this novel syndrome and KD, although they 
probably share several pathways to activate the so 
called ‘cytokine storm’. Future data and clinical infor-
mations will provide insights into the pathophysiology 
and will increase our understanding of KD. Programs 
of national surveillance are, consequently, of great im-
portance. 
Further studies evaluating predisposing factors 
and pathogenesis of this hyperinflammatory syndrome 
are needed to optimally manage this condition, as well 
as adding insight to long term follow-up of pediatric 
Covid-19 survivors.  
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of KD is the highest, is noteworthy. Some  authors 
speculate regarding variation in the virus  affecting 
areas with cases of hyperinflammatory  syndrome or 
increased susceptibility or genomic variation of these 
populations (32).
Therapy and Outcome
Intravenous immunoglobulins were apparently 
effective in these patients: their immunomodulatory 
properties are not specific but result in strong anti- 
inflammatory effects. Prompt treatment with IVIG 2 
gr/kg, however, implies infusion of large amount of flu-
ids: it has been suggested to infuse them divided into 
two separate doses and to use preferably high concen-
trated products. In case of obesity (BMI>30), reducing 
20% of therapeutic dose may avoid renal complications 
linked to the increase in oncotic pressure and blood 
viscosity (4).
In one recent review, Nakra propose to treat all the 
patients meeting criteria for KD (IVIG+acetylsalicylic 
acid) (32). Moreover, IVIG could have beneficial im-
munomodulatory effects also in patients who do not 
meet these criteria.
Licciardi et al. detailed improvement of both pa-
tients described after high-dose steroid use (methyl-
prednisolone iv, followed by prednisone per os) (10). In 
one case also IVIG were administered. Moreover, Ver-
doni et al. support the need to start adjunctive steroids 
in patients with features resembling MAS: steroids, on 
the basis of their experience, are safe and effective (6). 
Concerns exist regarding the safety of steroids in 
the setting of active COVID-19 infection, but no con-
clusions can be made with the current evidences, al-
though preliminary data suggest that the combination 
of mechanical ventilation and dexamethasone resulted 
in lower 28-days mortality in adults compared to those 
receiving mechanical ventilation alone (33).
Considering this hyperinflammatory syndrome as 
a post-infectious process, the immunosuppressive ef-
fects of the therapy would not risk flaring the infec-
tion. Precaution should be used if real-time PCR for 
SARS-CoV-2 results positive, suggesting active infec-
tion. 
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